# OnCo record tnbc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tnbc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tnbc" ;
  schema:name "Triple-negative breast cancer (TNBC)"@en ;
  schema:description "A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."@en ;
  schema:url <https://onco.cc/cancers/tnbc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Triple-negative_breast_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7843332> ;
  schema:citation <https://en.wikipedia.org/wiki/Triple-negative_breast_cancer>, <https://seer.cancer.gov/statfacts/html/breast-subtypes.html>, <https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/triple-negative-breast-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/mortality>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival>, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/risk-factors>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/survival>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/number-stages>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/tnm-staging>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/risks-causes/family-history-and-inherited-genes>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/symptoms>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/getting-diagnosed/tests>, <https://www.nhs.uk/tests-and-treatments/breast-screening-mammogram/who-breast-screening-is-for/>, <https://www.nice.org.uk/guidance/cg164/chapter/Recommendations>, <https://www.nice.org.uk/guidance/ng101/chapter/Recommendations>, <https://www.nice.org.uk/guidance/ng12/chapter/Recommendations-organised-by-site-of-cancer>, <https://doi.org/10.1093/jnci/dju055>, <https://doi.org/10.1158/1055-9965.EPI-17-0627>, <https://doi.org/10.1002/cncr.32207>, <https://doi.org/10.1002/cncr.22618>, <https://doi.org/10.1001/jama.295.21.2492>, <https://doi.org/10.1200/jco.2008.19.6873>, <https://doi.org/10.1097/ppo.0000000000000500>, <https://doi.org/10.1038/s41416-021-01409-7>, <https://doi.org/10.1038/bjc.2013.650>, <https://doi.org/10.1016/s1470-2045(17)30891-4>, <https://doi.org/10.1158/1055-9965.epi-11-0775>, <https://doi.org/10.1200/jco.2008.16.6231>, <https://doi.org/10.1200/jco.2014.57.1414>, <https://doi.org/10.1007/s10549-014-2980-0>, <https://doi.org/10.1200/jco.19.01907>, <https://doi.org/10.1093/jnci/djac117>, <https://doi.org/10.1093/jnci/dju237>, <https://doi.org/10.1007/s10549-012-2339-3>, <https://doi.org/10.1007/s10552-009-9331-1>, <https://doi.org/10.1158/1078-0432.ccr-06-3045>, <https://doi.org/10.1002/cncr.27581>, <https://doi.org/10.1002/cncr.23930>, <https://doi.org/10.1200/jco.2007.14.4147>, <https://doi.org/10.1038/s41523-017-0014-x>, <https://doi.org/10.1093/bjsopen/zrae138>, <https://doi.org/10.1200/jco.19.02309>, <https://doi.org/10.1200/jco.2018.77.8738>, <https://doi.org/10.1200/jco.22.02864>, <https://doi.org/10.1038/s41523-022-00448-4>, <https://doi.org/10.1016/j.lanepe.2024.100886>, <https://doi.org/10.1038/s41523-021-00308-7>, <https://doi.org/10.1111/his.14091>, <https://doi.org/10.1038/s41523-023-00554-x>, <https://doi.org/10.3390/cancers13225694>, <https://doi.org/10.1634/theoncologist.2012-0397>, <https://doi.org/10.1038/nature11412>, <https://doi.org/10.1172/jci45014>, <https://doi.org/10.1371/journal.pone.0157368>, <https://doi.org/10.1158/1078-0432.ccr-14-0432>, <https://doi.org/10.3322/caac.21393>, <https://doi.org/10.1001/jamaoncol.2017.4298>, <https://doi.org/10.1016/s0140-6736(05)66481-1>, <https://doi.org/10.1200/jco.2004.04.188>, <https://doi.org/10.1158/1078-0432.ccr-15-1465>, <https://doi.org/10.1093/jnci/djw177>, <https://doi.org/10.1016/s1470-2045(14)71171-4>, <https://doi.org/10.1093/jnci/90.18.1371>, <https://doi.org/10.1016/s0140-6736(19)32955-1>, <https://doi.org/10.1200/jco.2012.47.8313>, <https://www.nhs.uk/conditions/breast-cancer-in-women/treatment-for-breast-cancer-in-women/>, <https://www.nhs.uk/conditions/breast-cancer-in-women/tests-and-next-steps-for-breast-cancer-in-women/>, <https://www.nhs.uk/conditions/breast-cancer-in-women/help-and-support-for-breast-cancer-in-women/>, <https://www.macmillan.org.uk/cancer-information-and-support/breast-cancer/triple-negative-breast-cancer>, <https://breastcancernow.org/about-breast-cancer/diagnosis/types-of-breast-cancer/triple-negative-breast-cancer>, <https://www.nice.org.uk/guidance/ta851>, <https://www.nice.org.uk/guidance/ta886>, <https://www.nice.org.uk/guidance/ta801>, <https://www.nice.org.uk/guidance/ta819>, <https://tnbcfoundation.org/living-with-tnbc/newly-diagnosed>, <https://www.esmo.org/for-patients/patient-guides/breast-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/carboplatin-paclitaxel-ec-pembrolizumab>, <https://www.macmillan.org.uk/cancer-information-and-support/treatment/your-treatment-options/questions-to-ask-your-healthcare-team>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/chemotherapy>, <https://www.cancerresearchuk.org/about-cancer/breast-cancer/treatment/radiotherapy/radiotherapy-treatment>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/radiotherapy-for-breast-cancer>, <https://breastcancernow.org/about-breast-cancer/treatment/radiotherapy-for-primary-breast-cancer>, <https://www.cancerresearchuk.org/about-cancer/treatment/prehabilitation>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-breast-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/surgery-to-the-lymph-nodes-for-breast-cancer>, <https://breastcancernow.org/about-breast-cancer/awareness/breast-cancer-in-families/genetic-testing-for-altered-breast-cancer-genes>, <https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/causes-and-risk-factors/brca-gene>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/clinical-trials>, <https://doi.org/10.1056/NEJMoa2409932>, <https://doi.org/10.1056/NEJMoa1910549>, <https://doi.org/10.1056/NEJMoa1612645>, <https://doi.org/10.1056/NEJMoa2105215>, <https://doi.org/10.1016/j.annonc.2022.09.159>, <https://doi.org/10.1200/JCO.2015.63.1010>, <https://doi.org/10.1016/S1470-2045(21)00589-1>, <https://doi.org/10.1056/NEJMoa2202809>, <https://doi.org/10.1016/S0140-6736(20)30932-6>, <https://doi.org/10.1016/S1470-2045(13)70386-3>, <https://doi.org/10.1016/S0140-6736(17)31145-5>, <https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/olaparib>, <https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/olaparib-lynparza>, <https://breastcancernow.org/about-breast-cancer/treatment/targeted-therapy/pembrolizumab-keytruda>, <https://www.nhs.uk/tests-and-treatments/genetic-and-genomic-testing/>, <https://www.nhs.uk/tests-and-treatments/clinical-trials/>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/tiredness> ;
  onco:tag "spike", "breast" ;
  onco:related <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/roadmaps/trop2-adc-roadmap/>, <https://onco.cc/roadmaps/tnbc-history/>, <https://onco.cc/pairings/platinum-plus-hrd/>, <https://onco.cc/pairings/germline-to-parp/>, <https://onco.cc/collections/src-tnbc-foundation/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>, <https://onco.cc/cancers/inflammatory-breast-cancer/>, <https://onco.cc/cancers/tnbc-basal-like-1/>, <https://onco.cc/cancers/tnbc-basal-like-2/>, <https://onco.cc/cancers/tnbc-mesenchymal/>, <https://onco.cc/cancers/tnbc-mesenchymal-stem-like/>, <https://onco.cc/cancers/tnbc-luminal-androgen-receptor/>, <https://onco.cc/cancers/tnbc-immunomodulatory/>, <https://onco.cc/cancers/metaplastic-breast-carcinoma/>, <https://onco.cc/cancers/medullary-pattern-breast-carcinoma/>, <https://onco.cc/cancers/adenoid-cystic-carcinoma-breast/>, <https://onco.cc/cancers/apocrine-carcinoma-breast/>, <https://onco.cc/cancers/secretory-carcinoma-breast/>, <https://onco.cc/cancers/brca-associated-tnbc/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/roadmaps/tnbc-roadmap/>, <https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/>, <https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/>, <https://onco.cc/ideas/idea-tnbc-disparities-in-access-and-outcomes/>, <https://onco.cc/ideas/idea-tnbc-pd-l1-assay-harmonisation/>, <https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/>, <https://onco.cc/ideas/idea-tnbc-brain-metastasis-trials/>, <https://onco.cc/ideas/idea-tnbc-her2-ultralow-testing-uptake/>, <https://onco.cc/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/>, <https://onco.cc/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/>, <https://onco.cc/biomarkers/pd-l1-cps/>, <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/her2-low-ihc/>, <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/biomarkers/brca-germline/>, <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/hrd-positive/>, <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/trop2-expression/>, <https://onco.cc/biomarkers/pten-alteration/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/>, <https://onco.cc/biomarkers/akt1-e17k/>, <https://onco.cc/biomarkers/ctdna-mrd-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/trop2-pet/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/hypnosis-cancer-care/>, <https://onco.cc/technologies/lymphoedema-decongestive-therapy/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/scalp-cooling/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/acupuncture-chemotherapy-neuropathy/>, <https://onco.cc/technologies/acupuncture-hot-flushes/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/technologies/hrd-genomic-scar-scores/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/msi-mmr-testing/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/nectin4/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/targets/liv1/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/pten/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/palb2/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/notch1/>, <https://onco.cc/targets/mmr/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/atr/> ;
  onco:drugs <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/lunit-insight-mmg/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/ixabepilone/>, <https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/>, <https://onco.cc/drugs/ventana-pd-l1-sp263/>, <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/bracanalysis-cdx/>, <https://onco.cc/drugs/mychoice-cdx/>, <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/signatera/>, <https://onco.cc/drugs/guardant-reveal/>, <https://onco.cc/drugs/radar-mrd/>, <https://onco.cc/drugs/ventana-mmr-rxdx/>, <https://onco.cc/drugs/trusight-oncology-comprehensive/>, <https://onco.cc/drugs/tempus-xt-cdx/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/bicalutamide/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/veliparib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/denosumab/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:companies <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/systimmune/>, <https://onco.cc/companies/kelun-biotech/>, <https://onco.cc/companies/mabwell-shanghai-bioscience/>, <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/scancell/> ;
  onco:institutions <https://onco.cc/institutions/breast-cancer-now/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/guys-st-thomas/>, <https://onco.cc/institutions/barts-cancer-institute/>, <https://onco.cc/institutions/the-christie/>, <https://onco.cc/institutions/addenbrookes-cambridge/> ;
  onco:pathways <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/emt/>, <https://onco.cc/pathways/breast-cancer-signalling/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/notch/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/mismatch-repair-msi/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/er-pr-negative-threshold/>, <https://onco.cc/terms/her2-low-and-trop2-adc-eligibility-tnbc/>, <https://onco.cc/terms/pd-l1-cps-10-tnbc/>, <https://onco.cc/terms/hrd-in-breast-cancer/>, <https://onco.cc/terms/germline-brca-testing-criteria-tnbc/>, <https://onco.cc/terms/ki-67-in-tnbc/>, <https://onco.cc/terms/basal-like/>, <https://onco.cc/terms/claudin-low/>, <https://onco.cc/terms/androgen-receptor-positive-tnbc/>, <https://onco.cc/terms/ajcc-prognostic-stage-breast/>, <https://onco.cc/terms/interval-breast-cancer/>, <https://onco.cc/terms/risk-reducing-surgery-brca-carriers/>, <https://onco.cc/terms/chemoprevention-and-er-negative-breast-cancer/>, <https://onco.cc/terms/founder-mutation/>, <https://onco.cc/terms/idfs/>, <https://onco.cc/terms/luminal-androgen-receptor/>, <https://onco.cc/terms/pd-l1-assay-discordance/>, <https://onco.cc/terms/exceptional-responder/>, <https://onco.cc/terms/health-disparities/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/hair-loss-and-scalp-cooling-breast/>, <https://onco.cc/terms/menopause-after-chemotherapy-breast/>, <https://onco.cc/terms/body-image-after-breast-surgery/>, <https://onco.cc/terms/neutropenic-sepsis-breast-chemotherapy/>, <https://onco.cc/terms/adc-side-effects-breast/>, <https://onco.cc/terms/urgent-help-tnbc/>, <https://onco.cc/terms/work-and-money-breast-cancer-uk/>, <https://onco.cc/terms/carers-breast-cancer-uk/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/de-escalation/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/adc-sequencing/>, <https://onco.cc/terms/pam50/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/ocular-toxicity/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/peripheral-neuropathy/>, <https://onco.cc/terms/immune-colitis/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/sentinel-lymph-node-biopsy/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/stereotactic-radiosurgery/>, <https://onco.cc/terms/wbrt/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/radiation-dermatitis/>, <https://onco.cc/terms/deep-inspiration-breath-hold/>, <https://onco.cc/terms/clinical-trial/>, <https://onco.cc/terms/informed-consent/>, <https://onco.cc/terms/placebo/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/emotional-support-cancer-uk/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/anthracycline/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/tps/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/vus/>, <https://onco.cc/terms/tumour-informed-assay/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/brca-reversion-mutations/>, <https://onco.cc/terms/tnbc-trials-open-today/>, <https://onco.cc/terms/tnbc-residual-disease-decision/>, <https://onco.cc/terms/tnbc-symptom-control-palliation/> ;
  onco:trials <https://onco.cc/trials/tmist/>, <https://onco.cc/trials/nct06419621/>, <https://onco.cc/trials/nct06732323/>, <https://onco.cc/trials/nct07544056/>, <https://onco.cc/trials/nct07533123/>, <https://onco.cc/trials/nct06519370/>, <https://onco.cc/trials/start-b/>, <https://onco.cc/trials/import-low/>, <https://onco.cc/trials/nsabp-b39/>, <https://onco.cc/trials/eortc-22922/>, <https://onco.cc/trials/ma-20/>, <https://onco.cc/trials/dbcg-82bc/>, <https://onco.cc/trials/nct06767527/>, <https://onco.cc/trials/nct06393374/>, <https://onco.cc/trials/nct07669467/>, <https://onco.cc/trials/nct03671044/>, <https://onco.cc/trials/nct07111832/>, <https://onco.cc/trials/nct06966700/>, <https://onco.cc/trials/nct05347134/>, <https://onco.cc/trials/nct04915755/>, <https://onco.cc/trials/nct07173751/>, <https://onco.cc/trials/nct07679360/>, <https://onco.cc/trials/nct06279364/>, <https://onco.cc/trials/nct03997123/>, <https://onco.cc/trials/nct06841354/>, <https://onco.cc/trials/geparsixto/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/tropion-breast05/>, <https://onco.cc/trials/tnt/>, <https://onco.cc/trials/partner/>, <https://onco.cc/trials/fast-forward/>, <https://onco.cc/trials/impassion130/>, <https://onco.cc/trials/keynote-355/>, <https://onco.cc/trials/ascent/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/trials/destiny-breast06/>, <https://onco.cc/trials/i-spy-2/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/calgb-40603/>, <https://onco.cc/trials/neotrip/>, <https://onco.cc/trials/gepardouze/>, <https://onco.cc/trials/impassion030/>, <https://onco.cc/trials/a-brave/>, <https://onco.cc/trials/neopact/>, <https://onco.cc/trials/sysucc-001/>, <https://onco.cc/trials/geicam-ciboma/>, <https://onco.cc/trials/ea1131/>, <https://onco.cc/trials/bre12-158/>, <https://onco.cc/trials/c-trak-tn/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/trials/phoenix/>, <https://onco.cc/trials/barbican/>, <https://onco.cc/trials/keynote-119/>, <https://onco.cc/trials/ipatunity130/>, <https://onco.cc/trials/brocade3/>, <https://onco.cc/trials/diamond/>, <https://onco.cc/trials/lotus/>, <https://onco.cc/trials/pakt/>, <https://onco.cc/trials/scan-b/>, <https://onco.cc/trials/impassion031/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/trials/brightness/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/trials/scarlet-s2212/>, <https://onco.cc/trials/nct06112379/>, <https://onco.cc/trials/nct03742102/> ;
  onco:people <https://onco.cc/people/jean-abraham/>, <https://onco.cc/people/ellen-copson/>, <https://onco.cc/people/anne-armstrong/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-shah-tnbc-clonal-evolution-nature-2012/>, <https://onco.cc/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/>, <https://onco.cc/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/>, <https://onco.cc/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/>, <https://onco.cc/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/>, <https://onco.cc/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/>, <https://onco.cc/key-papers/paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019/>, <https://onco.cc/key-papers/paper-bertucci-metastatic-breast-genomics-nature-2019/>, <https://onco.cc/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/>, <https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/>, <https://onco.cc/key-papers/paper-shimelis-tnbc-risk-genes-jnci-2018/>, <https://onco.cc/key-papers/paper-sharma-tnbc-registry-germline-brca-bcrt-2014/>, <https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/>, <https://onco.cc/key-papers/paper-zheng-nigerian-inherited-breast-cancer-jco-2018/>, <https://onco.cc/key-papers/paper-huo-tcga-ancestry-breast-jama-oncol-2017/>, <https://onco.cc/key-papers/paper-martini-african-ancestry-tnbc-cancer-discov-2022/>, <https://onco.cc/key-papers/paper-donenberg-bahamas-brca1-founder-bcrt-2011/>, <https://onco.cc/key-papers/paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015/>, <https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/>, <https://onco.cc/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/>, <https://onco.cc/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/>, <https://onco.cc/key-papers/paper-ren-tnbc-mmr-msi-440-front-oncol-2021/>, <https://onco.cc/key-papers/paper-kurata-japanese-tnbc-msi-breast-cancer-2020/>, <https://onco.cc/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/>, <https://onco.cc/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019/>, <https://onco.cc/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/>, <https://onco.cc/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/>, <https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/>, <https://onco.cc/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/>, <https://onco.cc/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/>, <https://onco.cc/key-papers/paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014/>, <https://onco.cc/key-papers/paper-wang-notch-pest-mutations-tnbc-ccr-2015/>, <https://onco.cc/key-papers/paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012/>, <https://onco.cc/key-papers/paper-herschkowitz-rb1-loss-basal-like-bcr-2008/>, <https://onco.cc/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/>, <https://onco.cc/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/>, <https://onco.cc/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/>, <https://onco.cc/key-papers/paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020/>, <https://onco.cc/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/>, <https://onco.cc/key-papers/paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026/>, <https://onco.cc/key-papers/paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026/>, <https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/>, <https://onco.cc/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/>, <https://onco.cc/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/>, <https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/>, <https://onco.cc/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/>, <https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/>, <https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/>, <https://onco.cc/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/>, <https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/> ;
  onco:journals <https://onco.cc/journals/breast-cancer-jbcs/>, <https://onco.cc/journals/breast-cancer-research/>, <https://onco.cc/journals/breast-cancer-research-and-treatment/>, <https://onco.cc/journals/clinical-breast-cancer/>, <https://onco.cc/journals/journal-of-mammary-gland-biology-and-neoplasia/>, <https://onco.cc/journals/the-breast/>, <https://onco.cc/journals/the-breast-journal/> ;
  onco:pipeline <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/trials/tropion-breast05/>, <https://onco.cc/trials/izabright-breast01/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/trials/scarlet-s2212/>, <https://onco.cc/technologies/trop2-pet/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/puxitatug-samrotecan/>, <https://onco.cc/technologies/dual-payload-adc/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/ak146d1/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/oleclumab/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/esg401/>, <https://onco.cc/drugs/bebt-209/>, <https://onco.cc/drugs/jskn016/>, <https://onco.cc/drugs/fda018-adc/>, <https://onco.cc/drugs/avzo-021/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/lp-184/>, <https://onco.cc/drugs/tenalisib/>, <https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/>, <https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/>, <https://onco.cc/ideas/idea-tnbc-disparities-in-access-and-outcomes/>, <https://onco.cc/ideas/idea-tnbc-pd-l1-assay-harmonisation/>, <https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/>, <https://onco.cc/ideas/idea-tnbc-brain-metastasis-trials/>, <https://onco.cc/ideas/idea-tnbc-her2-ultralow-testing-uptake/>, <https://onco.cc/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/>, <https://onco.cc/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/nct06112379/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/trials/partner/>, <https://onco.cc/trials/phoenix/>, <https://onco.cc/trials/diamond/>, <https://onco.cc/trials/barbican/> ;
  onco:standardOfCare <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/trials/keynote-522/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/keynote-355/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/trials/ascent-03/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/interval-breast-cancer/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/er-pr-negative-threshold/>, <https://onco.cc/terms/her2-low-and-trop2-adc-eligibility-tnbc/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/germline-brca-testing-criteria-tnbc/>, <https://onco.cc/cancers/brca-associated-tnbc/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/terms/risk-reducing-surgery-brca-carriers/>, <https://onco.cc/terms/chemoprevention-and-er-negative-breast-cancer/>, <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/terms/tnm-staging/>, <https://onco.cc/terms/ajcc-prognostic-stage-breast/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/trials/keynote-522/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-522/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/tnbc-residual-disease-decision/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/ea1131/>, <https://onco.cc/trials/bre12-158/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/swog-s1418/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/targets/brca/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/lymphoedema-decongestive-therapy/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/trials/fast-forward/>, <https://onco.cc/trials/start-b/>, <https://onco.cc/trials/import-low/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/deep-inspiration-breath-hold/>, <https://onco.cc/terms/radiation-dermatitis/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/targets/brca/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/targets/brca/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/trials/keynote-355/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/ascent/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/ocular-toxicity/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/stereotactic-radiosurgery/>, <https://onco.cc/terms/wbrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/terms/tnbc-symptom-control-palliation/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/terms/clinical-trial/>, <https://onco.cc/terms/informed-consent/>, <https://onco.cc/terms/placebo/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/trials/scarlet-s2212/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/trials/geparsixto/>, <https://onco.cc/trials/brightness/>, <https://onco.cc/trials/calgb-40603/>, <https://onco.cc/drugs/veliparib/>, <https://onco.cc/trials/neotrip/>, <https://onco.cc/trials/gepardouze/>, <https://onco.cc/trials/impassion030/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/partner/>, <https://onco.cc/trials/tnt/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/cancers/brca-associated-tnbc/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/trials/brocade3/>, <https://onco.cc/drugs/veliparib/>, <https://onco.cc/trials/tnt/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/tnbc-symptom-control-palliation/>, <https://onco.cc/terms/bone-metastases/>, <https://onco.cc/drugs/denosumab/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/ild/> .